TY - JOUR AU - Bruix, J; Qin, S; Merle, P TI - Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet VL - 389 PY - 2017 DO - 10.1016/S0140-6736(16)32453-9 L3 - PubMed-ID: 27932229 SP - 56 EP - 66 ER -